SML1695
RSV604
≥98% (HPLC)
Synonym(s):
(S)-1-(2-Fluorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea, RSV-604
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C22H17FN4O2
CAS Number:
Molecular Weight:
388.39
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Product Name
RSV604, ≥98% (HPLC)
InChI key
MTPVBMVUENFFLL-HXUWFJFHSA-N
SMILES string
O=C(N1)[C@@H](NC(NC2=CC=CC=C2F)=O)N=C(C3=CC=CC=C3)C4=C1C=CC=C4
assay
≥98% (HPLC)
form
film
storage condition
protect from light
color
white
solubility
DMSO: 20 mg/mL, clear
storage temp.
2-8°C
Quality Level
Biochem/physiol Actions
RSV604 (RSV-604) is a cell-permeable, non-cytotoxic benzodiazepine derivative that is reported to target respiratory syncytial virus (RSV) nucleoprotein (N) via affinity interaction.
RSV604 (RSV-604) is a cell-permeable, non-cytotoxic (CC50 >50 μM) benzodiazepine derivative that is reported to target respiratory syncytial virus (RSV) nucleoprotein (N) via affinity interaction (Kd = 134 μM) and display similar antiviral potency against 40 clinical human RSV isolates (Ave. EC50 = 800 nM), including both subtypes A and B. Although RSV604 displays host-dependent potency against RSV cellular replication (EC50 = 2 μM/HeLa, 1.8 μM/HEp-2, >50 μM/BHK-21 based on cellular viral F protein level 72 hrs post RSV A2 infection) and release (by >1,000,000-fold/HeLa vs. no effect/BHK-21 72 hrs post infection; [RSV604] = EC90), complete loss of infectivity of released RSV from RSV604-treated cells is observed in both HeLa and BHK-21 cultures. RSV604 is also active against bovine RSV, but inactive toward mouse pneumonia virus, human metapneumovirus or parainfluenza virus types 1 &3 (PIV1 &PIV3).
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Yuzhen Gao et al.
Molecules (Basel, Switzerland), 26(9) (2021-05-06)
Respiratory syncytial virus (RSV) is a major pathogen that causes severe lower respiratory tract infection in infants, the elderly and the immunocompromised worldwide. At present no approved specific drugs or vaccines are available to treat this pathogen. Recently, several promising
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service